TY - JOUR
T1 - Burden of chemotherapy in patients with relapsed/refractory acute myeloid leukemia in the United States
T2 - a retrospective claims database study
AU - Pandya, Bhavik J.
AU - Chen, Chi Chang
AU - McGuiness, Catherine B.
AU - Sullivan, Loretta
AU - Feng, Qi
AU - Walsh, Elise
AU - Borate, Uma
N1 - Publisher Copyright:
© 2022 Astellas Pharma. Published by Informa UK Limited, trading as Taylor & Francis Group.
PY - 2022
Y1 - 2022
N2 - Background: Real-world estimates of relapsed or refractory (R/R) acute myeloid leukemia (AML) chemotherapy episode costs are scarce. We quantified chemotherapy episode–related costs and healthcare resource use (HRU) in R/R AML. Research Design and Methods: This real-world, retrospective analysis of United States claims from IQVIA’s PharMetrics® Plus database (October 2008-September 2019) identified adults with R/R AML and ≥1 chemotherapy episode. Chemotherapy episode (ie, low- [LIC] or high-intensity [HIC] chemotherapy) costs and HRU were determined using inpatient, outpatient, and pharmacy claims. Results: Mean (SD) and median total all-cause healthcare costs per R/R AML chemotherapy episode were $230,799 ($300,770) and $129,117. Mean (SD) and median adjusted direct R/R AML chemotherapy episode costs were $116,384 ($151,425) and $63,298, with increases noted from the first to the second and subsequent episodes and with HIC. Hospitalizations were the major cost driver; 64.1% of patients had ≥1 hospitalization and 36% required an intensive care unit stay. Conclusions: R/R AML chemotherapy episode costs were high, with higher costs reported with HIC and increasing lines of chemotherapy. Hospitalizations were a main cost driver. Novel therapies with comparable or improved effectiveness and decreased need for hospitalizations versus chemotherapy may help alleviate the clinical and economic burden of R/R AML.
AB - Background: Real-world estimates of relapsed or refractory (R/R) acute myeloid leukemia (AML) chemotherapy episode costs are scarce. We quantified chemotherapy episode–related costs and healthcare resource use (HRU) in R/R AML. Research Design and Methods: This real-world, retrospective analysis of United States claims from IQVIA’s PharMetrics® Plus database (October 2008-September 2019) identified adults with R/R AML and ≥1 chemotherapy episode. Chemotherapy episode (ie, low- [LIC] or high-intensity [HIC] chemotherapy) costs and HRU were determined using inpatient, outpatient, and pharmacy claims. Results: Mean (SD) and median total all-cause healthcare costs per R/R AML chemotherapy episode were $230,799 ($300,770) and $129,117. Mean (SD) and median adjusted direct R/R AML chemotherapy episode costs were $116,384 ($151,425) and $63,298, with increases noted from the first to the second and subsequent episodes and with HIC. Hospitalizations were the major cost driver; 64.1% of patients had ≥1 hospitalization and 36% required an intensive care unit stay. Conclusions: R/R AML chemotherapy episode costs were high, with higher costs reported with HIC and increasing lines of chemotherapy. Hospitalizations were a main cost driver. Novel therapies with comparable or improved effectiveness and decreased need for hospitalizations versus chemotherapy may help alleviate the clinical and economic burden of R/R AML.
KW - Chemotherapy
KW - healthcare resource use
KW - real-world cost analysis
KW - relapsed/refractory acute myeloid leukemia
UR - http://www.scopus.com/inward/record.url?scp=85135564172&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85135564172&partnerID=8YFLogxK
U2 - 10.1080/17474086.2022.2104709
DO - 10.1080/17474086.2022.2104709
M3 - Article
C2 - 35924860
AN - SCOPUS:85135564172
SN - 1747-4086
VL - 15
SP - 857
EP - 866
JO - Expert Review of Hematology
JF - Expert Review of Hematology
IS - 9
ER -